share_log

argenx SE | 6-K: argenx Announces Approval of VYVDURA Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

SEC announcement ·  Jan 18 00:00
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more